2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Levomecor Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 27 | 2023-08-17 | 2026-07-10 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 236 | 2021-03-30 | 2026-07-10 |
Depression (2) · Depressive Disorder, Major (2)
United States (2)
Paul Greene, PhD (2)